InnoCare Pharma Updates Nomination Committee Governance Framework

InnoCare Pharma Ltd. ( (HK:9969) ) just unveiled an announcement.

InnoCare Pharma Limited has formalized and disclosed the terms of reference for its Nomination Committee, which was originally established by its board in September 2019. The committee must comprise at least three directors, with a majority being independent non-executive directors and at least one member of a different gender, and will be chaired by either the board chairperson or an independent non-executive director.

The document sets out membership rules, tenure aligned with directors’ terms, quorum requirements and meeting procedures, mandating at least one meeting annually and empowering the board to appoint, remove or replace committee members. By clarifying governance responsibilities and aligning with Hong Kong Listing Rules and STAR Market requirements, InnoCare strengthens its corporate governance framework and signals attention to diversity and regulatory compliance for investors and other stakeholders.

The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.

More about InnoCare Pharma Ltd.

InnoCare Pharma Limited is a biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market, focusing on the research, development and commercialization of innovative drugs. The company operates through a board-driven governance structure with various specialized committees overseeing compliance, strategy and management oversight in key markets such as Greater China.

Average Trading Volume: 6,876,447

Technical Sentiment Signal: Sell

Current Market Cap: HK$17.58B

Find detailed analytics on 9969 stock on TipRanks’ Stock Analysis page.